Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.39 |
| ▸ | SPHK2 | Q9NRA0 | 5/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | TERT | O14746 | 1/20 | 0.34 |
| ▸ | PNP | P00491 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3174275 | 1.00 | HRH3 (0.40) | HRH3SPHK1SPHK2OPRD1POLB | |
| SCHEMBL1341604 | 0.85 | HRH3 (0.39) | HRH3SPHK1SPHK2OPRD1 | |
| SCHEMBL1341603 | 0.85 | HRH3 (0.39) | HRH3SPHK1SPHK2OPRD1 | |
| SCHEMBL3164195 | 0.79 | ALDH1A1 (0.37) | OPRD1POLB | |
| SCHEMBL3164203 | 0.79 | ALDH1A1 (0.37) | OPRD1POLB | |
| SCHEMBL1342058 | 0.79 | LMNA (0.42) | HRH3SPHK1SPHK2PARP1LMNA | |
| SCHEMBL1342060 | 0.79 | LMNA (0.42) | HRH3SPHK1SPHK2PARP1LMNA | |
| SCHEMBL1342061 | 0.79 | LMNA (0.42) | HRH3SPHK1SPHK2PARP1LMNA | |
| SCHEMBL1570996 | 0.78 | CCR2 (0.42) | POLBTERTLMNA | |
| SCHEMBL1569345 | 0.77 | CYP1A2 (0.41) | HRH3POLBL3MBTL1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071586-B2 | Heterocyclyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2011-12-06 | — | — | US | disclosed |
| WO-2010006938-A1 | NOVEL HETEROCYCLYL COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-21 | — | — | WO | disclosed |
| US-20100016282-A1 | NOVEL HETEROCYCLYL COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016282-A1 | NOVEL HETEROCYCLYL COMPOUNDS | CCR2, CCR3, CCR5 | HRH3 129/4885SPHK1 1015/4885SPHK2 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.